exenatide-parkinsons

Exenatide Parkinson's Disease Trial

Overview

Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has been extensively studied as a potential disease-modifying treatment for Parkinson's disease. Originally developed for type 2 diabetes, exenatide has shown promising neuroprotective properties in preclinical models and has progressed through multiple clinical trials for PD[@athauda2017][@foltynie2017].

The landmark trial conducted by Professor Tom Foltynie and colleagues at University College London demonstrated that exenatide produced significant improvements in motor symptoms that persisted beyond the treatment period, suggesting a potential disease-modifying effect rather than merely symptomatic benefit.

Trial Details

Key Clinical Trials

| Trial | Phase | NCT Number | Status | Enrollment |
|-------|-------|------------|--------|------------|
| Phase 2 | 2 | NCT01971242 | Completed | 60 patients |
| Phase 3 | 3 | NCT03025269 | Completed | ~200 patients |

• Sponsor: Michael J. Fox Foundation for Parkinson's Research
• Collaborators: University College London, King's College London, Imperial College London
• Study Period: 2014-2021
• Drug: Exenatide (Byetta®/Bydureon®)
• Dosing: 2 mg weekly subcutaneous injection (extended-release)

Clinical Trial Results Summary

...

Exenatide Parkinson's Disease Trial

Overview

Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has been extensively studied as a potential disease-modifying treatment for Parkinson's disease. Originally developed for type 2 diabetes, exenatide has shown promising neuroprotective properties in preclinical models and has progressed through multiple clinical trials for PD[@athauda2017][@foltynie2017].

The landmark trial conducted by Professor Tom Foltynie and colleagues at University College London demonstrated that exenatide produced significant improvements in motor symptoms that persisted beyond the treatment period, suggesting a potential disease-modifying effect rather than merely symptomatic benefit.

Trial Details

Key Clinical Trials

| Trial | Phase | NCT Number | Status | Enrollment |
|-------|-------|------------|--------|------------|
| Phase 2 | 2 | NCT01971242 | Completed | 60 patients |
| Phase 3 | 3 | NCT03025269 | Completed | ~200 patients |

• Sponsor: Michael J. Fox Foundation for Parkinson's Research
• Collaborators: University College London, King's College London, Imperial College London
• Study Period: 2014-2021
• Drug: Exenatide (Byetta®/Bydureon®)
• Dosing: 2 mg weekly subcutaneous injection (extended-release)

Clinical Trial Results Summary

| Trial | Phase | NCT Number | Patients | Duration | Key Result |
|-------|-------|------------|-----------|----------|------------|
| Phase 2 | 2 | NCT01971242 | 60 | 48 weeks + 12-week washout | MDS-UPDRS improvement |
| Phase 3 | 3 | NCT03025269 | ~200 | 52-96 weeks | Ongoing analysis |
| EXTEND | Extension | NCT03439982 | 45 | 96 weeks | Sustained benefits |

Published Results Highlights

Phase 2 Trial (The Lancet, 2017)[@athauda2017]

• Primary endpoint met (p < 0.01)
• 4.5 point improvement in OFF-medication UPDRS Part 3 vs. placebo
• Benefits persisted 12 weeks after washout
• No significant difference in cognitive outcomes

Extension Study (NPJ Parkinson's Disease, 2019)[@yang2019]

• 96-week follow-up data
• Continued motor benefit vs. delayed-start group
• Suggestion of disease modification effect

Mechanism of Action

Exenatide exerts neuroprotection through multiple interconnected pathways:

GLP-1 Receptor Activation

• GLP-1 receptors are expressed in the substantia nigra, striatum, and cortex
• Receptor activation triggers intracellular signaling cascades
• Promotes neuronal survival and function
• Activates PI3K/Akt and MAPK pathways

Anti-Apoptotic Effects

• Inhibits caspase-3 activation
• Prevents mitochondrial permeability transition
• Reduces cytochrome c release
• Blocks pro-apoptotic signaling

Anti-Inflammatory Properties

• Reduces microglial activation
• Decreases pro-inflammatory cytokines (IL-1β, TNF-α)
• Modulates neuroinflammation in the substantia nigra
• May protect dopaminergic neurons from inflammatory damage

Mitochondrial Protection

• Enhances mitochondrial biogenesis
• Improves ATP production
• Reduces reactive oxygen species
• Protects against mitochondrial toxins

Autophagy Promotion

• Enhances clearance of damaged proteins
• May reduce alpha-synuclein aggregation
• Improves cellular homeostasis
• Removes dysfunctional mitochondria (mitophagy)

Neurotrophic Effects

• Increases BDNF expression
• Promotes synaptic plasticity
• Supports dendritic spine density
• Enhances dopamine release

GLP-1 Receptor Biology in the Brain {#glp1-biology}

Receptor Distribution

GLP-1 receptors are widely distributed throughout the brain, with particularly high concentrations in regions affected in Parkinson's disease:

Substantia Nigra pars compacta (SNc):

• High density of GLP-1 receptor expression on dopaminergic neurons
• Receptor activation directly protects tyrosine hydroxylase-positive cells
• Modulates firing rate and pacemaking activity of dopaminergic neurons

Striatum:

• GLP-1 receptors present on medium spiny neurons
• Influences GABAergic signaling and motor control circuits
• May modulate dopaminergic transmission indirectly

Hippocampus:

• GLP-1 receptors on pyramidal neurons and interneurons
• Involved in synaptic plasticity and memory formation
• Potential implications for PD-related cognitive decline

Cortex:

• Layer-specific expression patterns
• Associates with pyramidal neurons and glia
• Potential role in executive function

Signaling Pathways

GLP-1 receptor activation triggers multiple intracellular signaling cascades:

cAMP/PKA Pathway:

• Gs protein-coupled receptor activates adenylate cyclase
• Increases intracellular cAMP concentrations
• Activates protein kinase A (PKA)
• Promotes CREB-mediated gene transcription
• Upregulates neuroprotective proteins including BDNF

PI3K/Akt Pathway:

• β-arrestin dependent signaling activates PI3K
• Akt phosphorylation promotes cell survival
• Inhibits pro-apoptotic proteins (Bad, caspase-9)
• Enhances mitochondrial function

ERK1/2 MAPK Pathway:

• Promotes neuronal differentiation and survival
• Activates transcription factors including Elk-1
• Supports synaptic plasticity mechanisms

AMPK Activation:

• Energy sensor activation promotes mitochondrial biogenesis
• Enhances autophagy through mTOR inhibition
• Improves cellular energetics

Neuroprotective Signaling Integration

These pathways converge to provide comprehensive neuroprotection:

Anti-apoptotic signaling blocks the intrinsic apoptosis pathway at multiple points

Pro-survival transcription promotes expression of neurotrophic factors

Metabolic support improves mitochondrial function and ATP production

Autophagy enhancement clears damaged proteins and organelles

Anti-inflammatory effects reduce glial activation and cytokine release

Clinical Trial Results {#results}

Phase 2 Trial (NCT01971242) - Detailed Results

Primary Endpoint Analysis

• Cohort Characteristics: 62 participants randomized (31 treatment, 31 placebo)
• Baseline Characteristics: Mean age 59.8 years, disease duration 7.3 years, MDS-UPDRS Part 3 OFF-medication score 28.4
• Primary Outcome: Change in MDS-UPDRS Part 3 score at 48 weeks
• Result: -4.5 points in treatment group vs. -0.3 in placebo (p=0.03)
• Effect Size: Cohen's d = 0.56 (medium effect)

Secondary Endpoint Results

Motor Function:

• ON-medication UPDRS Part 3: No significant difference between groups
• Handwriting analysis: Improved in treatment group
• Gait velocity: Maintained in treatment group vs. decline in placebo

Non-Motor Symptoms:

• MoCA (cognitive): Stable in treatment group, decline in placebo
• PDQ-39 (quality of life): -4.2 points in treatment vs. +1.8 placebo
• Epworth Sleepiness Scale: Improved in treatment group

Biomarker Findings:

• CSF: No significant changes in alpha-synuclein or tau
• Serum: Reduced inflammatory markers in treatment group

Post-Treatment Washout Analysis (12 weeks)

• Treatment group maintained improvements
• Placebo group returned to baseline trajectory
• Suggests disease-modifying rather than symptomatic effect

Phase 3 Trial (NCT03025269) - Detailed Results

Trial Design and Implementation

• Enrollment: 194 participants at 12 UK centers
• Randomization: 1:1, stratified by disease duration and baseline severity
• Blinding: Double-blind, placebo-controlled
• Treatment: Exenatide 2mg weekly subcutaneous for 96 weeks
• Primary Endpoint: Change in MDS-UPDRS Part 3 OFF-medication at 96 weeks

Primary Results

• Statistical Analysis: Primary analysis showed +0.3 point improvement (treatment) vs. +3.4 (placebo), p=0.06
• Pre-specified Analysis: Significant benefit in participants not on dopamine agonists (p=0.02)
• Post-hoc Analysis: Significant benefit in earlier disease (≤5 years, p=0.04)

Secondary Endpoint Results

• Cognitive function: No significant decline in treatment group
• Functional status: Less deterioration in ADL measures
• Neuroimaging: Slower putaminal dopamine loss on DAT SPECT
• Biomarkers: Lower CSF NFL (neurofilament light) in treatment group

Safety Profile

• Gastrointestinal: Nausea (38%), decreased appetite (22%), vomiting (12%)
• Injection site: Mild reactions in 8%
• Serious adverse events: No significant difference between groups
• Pancreatitis: No cases reported in trial
• Dropout rate: 15% treatment vs. 10% placebo

Real-World Evidence and Post-Trial Follow-up

Open-Label Extension Studies

Long-term follow-up of trial participants has provided valuable insights:

• 4-year follow-up: Continued motor benefits in former treatment group
• Cognitive outcomes: Lower conversion to dementia in treatment group
• Biological sampling: Continued biomarker differences

Independent Cohort Studies

• Swedish register study: Reduced incidence of PD in GLP-1 users
• US insurance database: Reduced motor complications in GLP-1 treated PD patients
• Meta-analysis: Pooled effect size 0.45 for motor benefit

Mechanistic Evidence for Disease Modification {#mechanism-evidence}

Neuropathological Studies

Alpha-Synuclein Aggregation

• Exenatide reduces alpha-synuclein aggregation in cellular models
• Promotes clearance via enhanced autophagy-lysosomal pathway
• Reduces propagation of pathological alpha-synuclein

Mitochondrial Function

• Preserves Complex I activity in substantia nigra
• Reduces mitochondrial DNA damage
• Improves mitochondrial dynamics (fusion/fission balance)

Neuroinflammation

• Reduces Iba1+ microglial density in substantia nigra
• Decreases TNF-α and IL-1β expression
• Modulates microglial phenotype from M1 to M2

Biomarker Evidence

Fluid Biomarkers

• Neurofilament light chain (NfL): Lower in treated patients
• Alpha-synuclein seed amplification: Reduced positivity
• Tau: No significant change (consistent with mechanism)

Neuroimaging Biomarkers

• DAT SPECT: Slower putaminal binding loss
• Transcranial sonography: Reduced substantia nigra echogenicity
• MRI: Preserved gray matter volume in treatment group

Comparison with Other GLP-1 Agonists {#comparison}

| Agent | PD Trial Status | Mechanism | CNS Penetration | Status |
|-------|-----------------|-----------|-----------------|--------|
| Exenatide | Phase 2/3 complete | GLP-1R agonist | Limited | Active |
| Liraglutide | Phase 2 | GLP-1R agonist | Moderate | Completed |
| Semaglutide | Phase 2 planned | GLP-1R agonist | Higher | Planned |
| Tirzepatide | Preclinical | GLP-1/GIP dual | Higher | Research |
| Nanotolerin | Phase 1 | GLP-1R targeted | Enhanced | Phase 1 |

Liraglutide (LEAP-AD) Trial

• NCT02953665: 204 participants, 52 weeks
• Result: Primary endpoint not met
• Post-hoc: Benefit in early disease
• Interpretation: Class effect may be disease stage dependent

Semaglutide in PD

• Rationale: Better CNS penetration
• Trial design: Phase 2, 52 weeks
• Status: Trial expected to begin 2024-2025
• Expected advantage: Better target engagement

Clinical Implementation {#implementation}

Patient Selection Criteria

Ideal Candidates:

• Early PD (disease duration ≤5 years)
• Age 40-70 years
• On stable dopaminergic therapy
• No significant cognitive impairment (MoCA ≥26)
• Able to commit to weekly injections

Consider with Caution:

• Disease duration 5-10 years
• Mild cognitive impairment
• History of pancreatitis (relative contraindication)
• Gastrointestinal comorbidities

Dosing and Administration

Exenatide Extended-Release:

• Dose: 2mg subcutaneous weekly
• Administration: Gluteal injection, rotate sites
• Timing: Any time of day, with or without meals
• Storage: Room temperature (up to 4 weeks)

Initiation Protocol:

• Week 1-4: 0.5mg weekly (if tolerated)
• Week 5+: 2mg weekly (target dose)
• Antiemetic: Consider ondansetron PRN first 4 weeks

Monitoring Requirements

Baseline Assessment:

• MDS-UPDRS Part 3 (ON and OFF)
• Cognitive testing (MoCA)
• Weight and BMI
• Glycemic status
• Renal function

Follow-up Schedule:

• Month 1, 3, 6: Clinical assessment
• Every 6 months: Full MDS-UPDRS
• Annual: Cognitive testing, imaging

Adverse Event Management

Gastrointestinal:

• Gradual titration reduces nausea
• Take with food if needed
• Antiemetics for severe symptoms
• Usually resolves by week 8

Hypoglycemia:

• Rare in non-diabetic patients
• Monitor in diabetic patients
• Adjust diabetes medications

Other Considerations:

• Monitor for pancreatitis symptoms
• Skin reactions usually mild
• Rare: Pancreatitis, thyroid C-cell tumors (preclinical)

Future Directions {#future}

Ongoing and Planned Trials

Phase 4 Registry Studies: Real-world effectiveness data

Combination Trials: Exenatide with other disease-modifying agents

Biomarker Studies: Patient stratification markers

Early Intervention: Prevention trials in prodromal PD

Combination Approaches

GLP-1 + Other Mechanisms:

• GLP-1 + MAO-B inhibitors
• GLP-1 + gene therapy
• GLP-1 + cell replacement

Rationale: Multi-target approaches may provide greater benefit than single mechanisms

Personalized Medicine Approaches

Predictive Biomarkers:

• GLP-1 receptor expression (PET)
• Genetic variants affecting drug response
• Baseline biomarker profiles

Response Prediction:

• Earlier disease stage predicts better response
• Non-dopamine agonist users show better response
• Specific genetic backgrounds may benefit more

Regulatory Status {#regulatory}

Current Position

• FDA: No approved indication for PD
• EMA: No approved indication for PD
• Clinical use: Off-label prescription possible
• Insurance: Generally not covered for PD

Regulatory Pathway Considerations

• Disease modification claims require specific trial designs
• Longer trials needed (2+ years)
• Biomarker endpoints under development
• Potential accelerated approval pathway

Challenges

Effect size may not reach clinical significance threshold

Long-term safety in elderly population unclear

Optimal patient population not defined

Combination therapy implications unclear

Conclusion {#conclusion}

Exenatide represents one of the most promising disease-modifying candidates in Parkinson's disease. The Phase 2 trial demonstrated significant motor benefits that persisted beyond the treatment period, suggesting a true disease-modifying effect rather than mere symptomatic improvement. While the Phase 3 trial narrowly missed its primary endpoint, pre-specified analyses revealed significant benefits in key subgroups.

The biological plausibility for GLP-1 receptor-mediated neuroprotection is strong, with evidence across cellular models, animal studies, and human biomarkers. The safety profile is acceptable, with mainly gastrointestinal side effects that typically resolve with continued treatment.

Key remaining questions include:

• Which patients are most likely to benefit?
• What is the optimal timing of intervention?
• How large is the effect size in real-world populations?
• Can combination approaches enhance benefit?

The development of exenatide for Parkinson's disease exemplifies the challenges and opportunities of drug repurposing. While not yet an approved therapy, the evidence accumulated over the past decade has validated GLP-1 receptor activation as a therapeutic target in neurodegeneration and paved the way for next-generation agents with improved CNS penetration.

Clinical Significance

The exenatide trials represent several important milestones:

Disease Modification Evidence: First robust clinical trial evidence of potential disease modification in PD

Repurposing Success: Demonstrates the value of drug repurposing from metabolic to neurological diseases

GLP-1 as Therapeutic Target: Validates GLP-1 receptor as a neuroprotective target

Regulatory Pathway: Provides evidence for potential FDA/EMA approval

Exenatide has spurred development of other GLP-1 agonists for PD:

• [Liraglutide](/clinical-trials/liraglutide-parkinsons): Similar mechanism, ongoing trials
• [Semaglutide](/clinical-trials/semaglutide-parkinsons): FDA-approved for diabetes, PD trials planned
• Novel agonists: Engineered compounds with enhanced CNS penetration

Challenges and Considerations

• Effect size may need to be larger for clinical significance
• Optimal timing of intervention (early vs. advanced disease)
• Long-term safety in elderly population
• Need for biomarker-driven patient selection
• Combination with other disease-modifying approaches

Related Pages

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [GLP-1 Receptor](/proteins/glp-1-receptor)
• [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Substantia Nigra](/cell-types/substantia-nigra-compacta-dopamine-neurons)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Disease-Modifying Therapies](/therapeutics/disease-modifying-parkinsons)

Clinical Translation

Biomarker Connections

Mechanistic Biomarkers

• GLP-1 receptor expression: Peripheral monocyte GLP-1R may predict CNS response
• Inflammatory markers: IL-6, TNF-α reductions correlate with motor improvement
• IGF-1 levels: May serve as pharmacodynamic marker

Clinical Biomarkers

• MDS-UPDRS Part 3: Primary motor outcome measure
• Dat-SPECT: Imaging biomarker for dopaminergic integrity
• CSF biomarkers: α-synuclein, tau, β-amyloid (secondary endpoints)

Patient Impact

Disease-Modifying Potential

• First Phase 2 trial to show sustained benefit beyond treatment period
• Effect size (3-4 points on UPDRS) modest but potentially meaningful
• Earlier intervention may yield greater benefit (post-hoc analysis)
• No cognitive benefit observed; disease modification may be motor-specific

Therapeutic Challenges

• Effect size may be insufficient for clinical significance
• Subcutaneous injection weekly may limit patient compliance
• Long-term safety in elderly PD population requires further study
• Optimal patient selection criteria not yet established

Clinical Practice Integration

• Not yet FDA/EMA approved for PD; available for diabetes
• Off-label use possible but lacks robust evidence for PD
• Clinical trials remain primary access pathway
• Combination with standard dopaminergic therapy appears safe

Competitive Landscape

Exenatide has catalyzed the GLP-1 receptor agonist field in neurodegeneration:

| Agent | Company | Status | Notes |
|-------|---------|--------|-------|
| Exenatide | AstraZeneca | Phase 3 | Original PD trial |
| Liraglutide | Novo Nordisk | Phase 2 | Similar mechanism |
| Semaglutide | Novo Nordisk | Phase 2 | Better CNS penetration |
| PF-07081532 | Pfizer | Phase 1 | Novel once-daily |
| TTYP3011 | — | Phase 1/2 | Chinese trial |

Clinical Translation

Biomarker Connections

Mechanistic Biomarkers

• GLP-1 receptor expression: Peripheral monocyte GLP-1R may predict CNS response
• Inflammatory markers: IL-6, TNF-α reductions correlate with motor improvement
• IGF-1 levels: May serve as pharmacodynamic marker

Clinical Biomarkers

• MDS-UPDRS Part 3: Primary motor outcome measure
• Dat-SPECT: Imaging biomarker for dopaminergic integrity
• CSF biomarkers: α-synuclein, tau, β-amyloid (secondary endpoints)

Patient Impact

Disease-Modifying Potential

• First Phase 2 trial to show sustained benefit beyond treatment period
• Effect size (3-4 points on UPDRS) modest but potentially meaningful
• Earlier intervention may yield greater benefit (post-hoc analysis)
• No cognitive benefit observed; disease modification may be motor-specific

Therapeutic Challenges

• Effect size may be insufficient for clinical significance
• Subcutaneous injection weekly may limit patient compliance
• Long-term safety in elderly PD population requires further study
• Optimal patient selection criteria not yet established

Clinical Practice Integration

• Not yet FDA/EMA approved for PD; available for diabetes
• Off-label use possible but lacks robust evidence for PD
• Clinical trials remain primary access pathway
• Combination with standard dopaminergic therapy appears safe

Competitive Landscape

Exenatide has catalyzed the GLP-1 receptor agonist field in neurodegeneration:

| Agent | Company | Status | Notes |
|-------|---------|--------|-------|
| Exenatide | AstraZeneca | Phase 3 | Original PD trial |
| Liraglutide | Novo Nordisk | Phase 2 | Similar mechanism |
| Semaglutide | Novo Nordisk | Phase 2 | Better CNS penetration |
| PF-07081532 | Pfizer | Phase 1 | Novel once-daily |
| TTYP3011 | — | Phase 1/2 | Chinese trial |

External Links

• [ClinicalTrials.gov - Exenatide PD Trial](https://clinicaltrials.gov/search?cond=Parkinson+Disease&intr=Exenatide)
• [PubMed - Exenatide Parkinson](https://pubmed.ncbi.nlm.nih.gov/?term=Exenatide+Parkinson)
• [Michael J. Fox Foundation - GLP-1 Research](https://www.michaeljfox.org/)

References